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Background
Initial data from a Phase I/II study in patients with
recently diagnosed metastatic RCC (NCT01525017)
demonstrated that intratumoral administration of a cell
based allogeneic vaccine adjuvant before nephrectomy
was associated with a prominent intratumoral infiltra-
tion of CD8+ T cells in a majority of patients and a
trend towards prolonged survival was noted (Journal of
Clinical Oncology, 2014 ASCO Annual Meeting
Abstracts. Vol 32, No 15_suppl,, 2014: 3085)
Methods
Long-term survival as well as data on tumor response
after subsequent TKI treatment has been studied.
Results
Median overall survival (mOS) for MSKCC intermediate
risk patients (n = 5) or high risk patients (n = 6) is still
not reached but is currently (08JUL2015) 29.0 and 26.0
months, respectively. Three out of 6 patients who to
date have received subsequent treatment with TKIs have
experienced an objective tumor response. One sunitinib-
responding patient (high risk), exhibited an extensive
sarcomatoid transformation of the resected primary
tumor. Another patient (high risk) who developed 4
brain metastases 4 months after vaccination responded
with a complete disappearance of all 4 brain lesions and
is still free from CNS-lesions 21 months after initiation
of sunitinib. Both patients exhibited a strong/massive
intratumoral infiltration of CD8+ T cells in their
removed kidney tumor.
Conclusions
The current mOS (26.0 months) in high-risk patients has
by far surpassed reported mOS of 9.0 months in compar-
able high-risk patients with recently diagnosed mRCC
receiving upfront mono-therapy with sunitinib before
nephrectomy. The objective tumor responses seen in two
high risk patients after addition of sunitinib is surprising
since historical data indicate that brain metastases as well
as extensive sarcomatoid transformation are higly resis-
tant to sunitinib treatment. Our findings indicate that
intratumoral administration of an off-the-shelf vaccine
adjuvant consisting of activated allogeneic DCs induces a
CTL-mediated anti-tumor response that may prolong
survival in mRCC-patients. Data on patients who have
received additional treatment with sunitinib (known to
deplete myeloid-derived suppressor cells) indicate a
synergistic anti-tumoral effect. A multi-centre Phase II
study (NCT02432846) has recently been initiated.
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